Adriana Celesia

Verona, 37134, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

First-in-Class Covalent Inhibitors of PFKFB3: Discovery and Characterization in PDAC Models.

First-in-Class Covalent Inhibitors of PFKFB3: Discovery and Characterization in PDAC Models.

Journal: Journal of medicinal chemistry

Published: May 26, 2026

Onconase Induces Apoptosis in Dabrafenib-Resistant Melanoma Cell Lines Through Dysregulation of ROS Homeostasis, Antioxidant Protein Expression, and Mitochondrial Dynamics.

Onconase Induces Apoptosis in Dabrafenib-Resistant Melanoma Cell Lines Through Dysregulation of ROS Homeostasis, Antioxidant Protein Expression, and Mitochondrial Dynamics.

Journal: International journal of molecular sciences

Published: December 30, 2025

Extracellular vesicles from long COVID patients promote RUNX2-mediated cellular stress via dysregulated miR-204 and p53 pathway activation.

Extracellular vesicles from long COVID patients promote RUNX2-mediated cellular stress via dysregulated miR-204 and p53 pathway activation.

Journal: Cell communication and signaling : CCS

Published: June 06, 2025

Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells.

Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells.

Journal: Cell death & disease

Published: March 31, 2025

Mutant p53 affects the mitochondrial proteome, promoting mitochondrial fragmentation and OXPHOS in pancreatic ductal adenocarcinoma cells.

Mutant p53 affects the mitochondrial proteome, promoting mitochondrial fragmentation and OXPHOS in pancreatic ductal adenocarcinoma cells.

Journal: The FEBS journal

Published: January 17, 2025

Long non-coding RNA H19 enhances the pro-apoptotic activity of ITF2357 (a histone deacetylase inhibitor) in colorectal cancer cells.

Long non-coding RNA H19 enhances the pro-apoptotic activity of ITF2357 (a histone deacetylase inhibitor) in colorectal cancer cells.

Journal: Frontiers in pharmacology

Published: August 10, 2023

Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat).

Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat).

Journal: International journal of molecular sciences

Published: April 19, 2023

The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis.

The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis.

Journal: Biomedicines

Published: May 25, 2022

Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties.

Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties.

Journal: Biomedicines

Published: January 26, 2022

The Good and Bad of Nrf2: An Update in Cancer and New Perspectives in COVID-19.

The Good and Bad of Nrf2: An Update in Cancer and New Perspectives in COVID-19.

Journal: International journal of molecular sciences

Published: July 01, 2021

Tributyltin(IV) Butyrate: A Novel Epigenetic Modifier with ER Stress- and Apoptosis-Inducing Properties in Colon Cancer Cells.

Tributyltin(IV) Butyrate: A Novel Epigenetic Modifier with ER Stress- and Apoptosis-Inducing Properties in Colon Cancer Cells.

Journal: Molecules (Basel, Switzerland)

Published: June 30, 2021

ROS-Dependent ER Stress and Autophagy Mediate the Anti-Tumor Effects of Tributyltin (IV) Ferulate in Colon Cancer Cells.

ROS-Dependent ER Stress and Autophagy Mediate the Anti-Tumor Effects of Tributyltin (IV) Ferulate in Colon Cancer Cells.

Journal: International journal of molecular sciences

Published: September 30, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026